Bruno C. Medeiros
YOU?
Author Swipe
View article: 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed <i>FLT3</i> Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed <i>FLT3</i> Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years Open
Background: C10603/RATFIY was the first AML trial to show the benefit of adding a targeted agent to intensive chemotherapy for a specific genetically determined subset (Stone R et al, NEJM 2017). The addition of the multi-kinase inhibitor …
View article: CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia
CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia Open
Background Acute Myeloid leukemia is a heterogeneous disease that requires novel targeted treatment options tailored to the patients’ specific microenvironment and blast phenotype. Methods We characterized bone marrow and/or blood samples …
View article: Supplementary Table 4 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Table 4 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Table 4. The raw median ion counts (per cell) for each marker (table heading) in each manually gated immunophenotypic population (columns) of each patient sample (rows) are shown.
View article: Supplementary Methods from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Methods from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Methods
View article: Supplementary Figure Legends from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Figure Legends from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Figure Legends
View article: Supplementary Figure 9 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Figure 9 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Figure 9. Gating strategy is shown for each population.
View article: Supplementary Table 5 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Table 5 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Table 5. Number of cell events collected for each sample.
View article: Supplementary Figures 1 - 8 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Figures 1 - 8 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Figure 1. SPADE plots of normal bone marrow sample no. 6. Supplementary Figure 2. The frequency of cells in the indicated (manually-gated) populations. Supplementary Figure 3. Multi-dimensional binning analysis of the CD34+CD…
View article: Supplementary Tables 1 - 3 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Tables 1 - 3 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Table 1. Clinical characteristics of AML patients tested in this study. Supplementary Table 2. Antibodies used in this study. Supplementary Table 3. Comparison of clinical (fluorescent) flow cytometry (on left), to mass cytom…
View article: Data from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Data from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Acute myeloid leukemia (AML) is characterized by a high relapse rate that has been attributed to the quiescence of leukemia stem cells (LSC), which renders them resistant to chemotherapy. However, this hypothesis is largely supported by in…
View article: Supplementary Figures 1 - 8 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Figures 1 - 8 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Figure 1. SPADE plots of normal bone marrow sample no. 6. Supplementary Figure 2. The frequency of cells in the indicated (manually-gated) populations. Supplementary Figure 3. Multi-dimensional binning analysis of the CD34+CD…
View article: Supplementary Figure Legends from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Figure Legends from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Figure Legends
View article: Supplementary Tables 1 - 3 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Tables 1 - 3 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Table 1. Clinical characteristics of AML patients tested in this study. Supplementary Table 2. Antibodies used in this study. Supplementary Table 3. Comparison of clinical (fluorescent) flow cytometry (on left), to mass cytom…
View article: Data from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Data from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Acute myeloid leukemia (AML) is characterized by a high relapse rate that has been attributed to the quiescence of leukemia stem cells (LSC), which renders them resistant to chemotherapy. However, this hypothesis is largely supported by in…
View article: Supplementary Methods from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Methods from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Methods
View article: Supplementary Table 4 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Table 4 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Table 4. The raw median ion counts (per cell) for each marker (table heading) in each manually gated immunophenotypic population (columns) of each patient sample (rows) are shown.
View article: Supplementary Figure 9 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Figure 9 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Figure 9. Gating strategy is shown for each population.
View article: Supplementary Table 5 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Supplementary Table 5 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy Open
Supplementary Table 5. Number of cell events collected for each sample.
View article: Supplementary Figure 1 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Supplementary Figure 1 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
(A) Cytotoxicity of ixazomib compared to MLN2238 (IC50 = 63.68 {plus minus} 5.3 nM) in OCI-AML3 cells. Plots of (B) GFP expression by K562 cells ectopically expressing constructs (C) treated with ixazomib.
View article: Supplementary Figure 1 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Supplementary Figure 1 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
(A) Cytotoxicity of ixazomib compared to MLN2238 (IC50 = 63.68 {plus minus} 5.3 nM) in OCI-AML3 cells. Plots of (B) GFP expression by K562 cells ectopically expressing constructs (C) treated with ixazomib.
View article: Data from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Data from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
Purpose: This study was performed to determine whether the investigational proteasome inhibitor ixazomib demonstrated selective antineoplastic activity against acute myelogenous leukemia cells expressing a mutated nucleophosmin-1 gene and …
View article: Supplementary Figure 4 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Supplementary Figure 4 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
(A) Representative FACS plot of sorted NPMc+ primary leukemic blasts (patient AML6) and (B) mRNA expression by qPCR using the same AML patient samples tested in Figure 4.
View article: Supplementary methods and figures from Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function
Supplementary methods and figures from Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function Open
This file contains additional data such as detailed sequencing methods; Sanger sequencing result; receptor expression and function of R308 and double cysteine mutations.
View article: Supplementary Table 1 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Supplementary Table 1 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
Primer sequences for GCLC, GCLM, NQO1, NRF2 and GAPDH analysis by real-time RT-PCR analysis.
View article: Supplementary Figure 5 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Supplementary Figure 5 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
In vivo analysis of patients AML1-3 including (A) H2O2 levels, (B) WBC counts of AML3 during ixazomib treatment (arrow marks when hydrea stopped), and (C) mRNA expression (AML2).
View article: Supplementary Figure 5 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Supplementary Figure 5 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
In vivo analysis of patients AML1-3 including (A) H2O2 levels, (B) WBC counts of AML3 during ixazomib treatment (arrow marks when hydrea stopped), and (C) mRNA expression (AML2).
View article: Data from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Data from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
Purpose: This study was performed to determine whether the investigational proteasome inhibitor ixazomib demonstrated selective antineoplastic activity against acute myelogenous leukemia cells expressing a mutated nucleophosmin-1 gene and …
View article: Data from Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function
Data from Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function Open
Exclusive of membrane-proximal mutations seen commonly in chronic neutrophilic leukemia (e.g., T618I), functionally defective mutations in the extracellular domain of the G-CSF receptor (CSF3R) have been reported only in severe congenital …
View article: Supplementary Figure 6 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Supplementary Figure 6 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species Open
Effects of combining ixazomib and Trichostatin A (TSA) (A, B, C), and of combining bortezomib and SAHA (D, E) in OCI-AML3 cells with or without depletion of NPMc+ expression.